TY - JOUR AU - Teuffel, O. AU - Leibundgut, K. AU - Lehrnbecher, T. AU - Alonzo, T. A. AU - Beyene, J. AU - Sung, L. PY - 2013 DA - 2013// TI - Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis JO - Br J Haematol VL - 161 UR - https://doi.org/10.1111/bjh.12233 DO - 10.1111/bjh.12233 ID - Teuffel2013 ER - TY - JOUR AU - Burnett, A. K. AU - Russell, N. H. AU - Hills, R. K. PY - 2015 DA - 2015// TI - A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2015-01-623447 DO - 10.1182/blood-2015-01-623447 ID - Burnett2015 ER - TY - JOUR AU - Piemontese, S. AU - Boumendil, A. AU - Labopin, M. PY - 2019 DA - 2019// TI - Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0751-4 DO - 10.1186/s13045-019-0751-4 ID - Piemontese2019 ER - TY - JOUR AU - Löwenberg, B. AU - Suciu, S. AU - Archimbaud, E. PY - 1998 DA - 1998// TI - Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group JO - J Clin Oncol. VL - 16 UR - https://doi.org/10.1200/JCO.1998.16.3.872 DO - 10.1200/JCO.1998.16.3.872 ID - Löwenberg1998 ER - TY - JOUR AU - Ferrero, D. AU - Crisà, E. AU - Marmont, F. PY - 2014 DA - 2014// TI - Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents JO - Ann Hematol VL - 93 UR - https://doi.org/10.1007/s00277-014-2047-7 DO - 10.1007/s00277-014-2047-7 ID - Ferrero2014 ER - TY - JOUR AU - Saygin, C. AU - Carraway, H. E. PY - 2017 DA - 2017// TI - Emerging therapies for acute myeloid leukemia JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0463-6 DO - 10.1186/s13045-017-0463-6 ID - Saygin2017 ER - TY - JOUR AU - Molica, M. AU - Breccia, M. AU - Foa, R. AU - Jabbour, E. AU - Kadia, T. M. PY - 2019 DA - 2019// TI - Maintenance therapy in AML: The past, the present and the future JO - Am J Hematol VL - 94 UR - https://doi.org/10.1002/ajh.25620 DO - 10.1002/ajh.25620 ID - Molica2019 ER - TY - JOUR AU - Lee, C. J. AU - Savani, B. N. AU - Mohty, M. PY - 2019 DA - 2019// TI - Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation JO - Bone Marrow Transplant VL - 54 UR - https://doi.org/10.1038/s41409-018-0286-2 DO - 10.1038/s41409-018-0286-2 ID - Lee2019 ER - TY - JOUR AU - Lai, C. AU - Doucette, K. AU - Norsworthy, K. PY - 2019 DA - 2019// TI - Recent drug approvals for acute myeloid leukemia JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0774-x DO - 10.1186/s13045-019-0774-x ID - Lai2019 ER - TY - JOUR AU - Schroeder, T. AU - Rautenberg, C. AU - Haas, R. AU - Germing, U. AU - Kobbe, G. PY - 2018 DA - 2018// TI - Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation JO - Int J Hematol VL - 107 UR - https://doi.org/10.1007/s12185-017-2364-4 DO - 10.1007/s12185-017-2364-4 ID - Schroeder2018 ER - TY - JOUR AU - Wang, Y. AU - Liu, Q. F. AU - Wu, D. P. PY - 2020 DA - 2020// TI - Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study JO - Sci China Life Sci VL - 63 UR - https://doi.org/10.1007/s11427-019-1610-2 DO - 10.1007/s11427-019-1610-2 ID - Wang2020 ER - TY - JOUR AU - Kantarjian, H. M. AU - Thomas, X. G. AU - Dmoszynska, A. PY - 2012 DA - 2012// TI - Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.9429 DO - 10.1200/JCO.2011.38.9429 ID - Kantarjian2012 ER - TY - JOUR AU - Dombret, H. AU - Seymour, J. F. AU - Butrym, A. PY - 2015 DA - 2015// TI - International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts JO - Blood VL - 126 UR - https://doi.org/10.1182/blood-2015-01-621664 DO - 10.1182/blood-2015-01-621664 ID - Dombret2015 ER - TY - JOUR AU - Jabbour, E. AU - Giralt, S. AU - Kantarjian, H. PY - 2009 DA - 2009// TI - Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24198 DO - 10.1002/cncr.24198 ID - Jabbour2009 ER - TY - JOUR AU - Lima, M. AU - Giralt, S. AU - Thall, P. F. PY - 2010 DA - 2010// TI - Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.25500 DO - 10.1002/cncr.25500 ID - Lima2010 ER - TY - JOUR AU - Pusic, I. AU - Choi, J. AU - Fiala, M. A. PY - 2015 DA - 2015// TI - Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome JO - Biol Blood Marrow Transplant VL - 21 UR - https://doi.org/10.1016/j.bbmt.2015.05.026 DO - 10.1016/j.bbmt.2015.05.026 ID - Pusic2015 ER - TY - JOUR AU - Ma, Y. AU - Qu, C. AU - Dai, H. PY - 2020 DA - 2020// TI - Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia JO - Bone Marrow Transplant VL - 55 UR - https://doi.org/10.1038/s41409-019-0677-z DO - 10.1038/s41409-019-0677-z ID - Ma2020 ER - TY - JOUR AU - Maples, K. T. AU - Sabo, R. T. AU - McCarty, J. M. AU - Toor, A. A. AU - Hawks, K. G. PY - 2018 DA - 2018// TI - Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies JO - Leuk Lymphoma VL - 59 UR - https://doi.org/10.1080/10428194.2018.1443334 DO - 10.1080/10428194.2018.1443334 ID - Maples2018 ER - TY - JOUR AU - Oshikawa, G. AU - Kakihana, K. AU - Saito, M. PY - 2015 DA - 2015// TI - Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia JO - Br J Haematol VL - 169 UR - https://doi.org/10.1111/bjh.13248 DO - 10.1111/bjh.13248 ID - Oshikawa2015 ER - TY - JOUR AU - Platzbecker, U. AU - Middeke, J. M. AU - Sockel, K. PY - 2018 DA - 2018// TI - Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30580-1 DO - 10.1016/S1470-2045(18)30580-1 ID - Platzbecker2018 ER - TY - JOUR AU - Lima, M. AU - Oran, B. AU - Champlin, R. E. PY - 2018 DA - 2018// TI - CC-486 Maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes JO - Biol Blood Marrow Transplant VL - 24 UR - https://doi.org/10.1016/j.bbmt.2018.06.016 DO - 10.1016/j.bbmt.2018.06.016 ID - Lima2018 ER - TY - JOUR AU - Gao, L. AU - Zhang, Y. AU - Wang, S. PY - 2020 DA - 2020// TI - Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter JO - Randomized Controlled Trial J Clin Oncol UR - https://doi.org/10.1200/JCO.19.03277 DO - 10.1200/JCO.19.03277 ID - Gao2020 ER - TY - JOUR AU - Bazarbachi, A. AU - Bug, G. AU - Baron, F. PY - 2020 DA - 2020// TI - Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation JO - Haematologica VL - 105 UR - https://doi.org/10.3324/haematol.2019.243410 DO - 10.3324/haematol.2019.243410 ID - Bazarbachi2020 ER - TY - JOUR AU - Antar, A. I. AU - Otrock, Z. K. AU - Jabbour, E. AU - Mohty, M. AU - Bazarbachi, A. PY - 2020 DA - 2020// TI - FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions JO - Leukemia VL - 34 UR - https://doi.org/10.1038/s41375-019-0694-3 DO - 10.1038/s41375-019-0694-3 ID - Antar2020 ER - TY - JOUR AU - Xuan, L. AU - Wang, Y. AU - Huang, F. PY - 2018 DA - 2018// TI - Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation JO - Cancer VL - 124 UR - https://doi.org/10.1002/cncr.31295 DO - 10.1002/cncr.31295 ID - Xuan2018 ER - TY - JOUR AU - Rollig, C. AU - Serve, H. AU - Huttmann, A. PY - 2015 DA - 2015// TI - Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00362-9 DO - 10.1016/S1470-2045(15)00362-9 ID - Rollig2015 ER - TY - JOUR AU - Xuan, L. AU - Wang, Y. AU - Chen, J. PY - 2019 DA - 2019// TI - Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation JO - Biol Blood Marrow Transplant VL - 25 UR - https://doi.org/10.1016/j.bbmt.2019.04.018 DO - 10.1016/j.bbmt.2019.04.018 ID - Xuan2019 ER - TY - JOUR AU - Yilmaz, M. AU - Alfayez, M. AU - DiNardo, C. D. PY - 2020 DA - 2020// TI - Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00964-5 DO - 10.1186/s13045-020-00964-5 ID - Yilmaz2020 ER - TY - JOUR AU - Chen, Y. B. AU - Li, S. AU - Lane, A. A. PY - 2014 DA - 2014// TI - Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia JO - Biol Blood Marrow Transplant VL - 20 UR - https://doi.org/10.1016/j.bbmt.2014.09.007 DO - 10.1016/j.bbmt.2014.09.007 ID - Chen2014 ER - TY - JOUR AU - Brunner, A. M. AU - Li, S. AU - Fathi, A. T. PY - 2016 DA - 2016// TI - Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission JO - Br J Haematol VL - 175 UR - https://doi.org/10.1111/bjh.14260 DO - 10.1111/bjh.14260 ID - Brunner2016 ER - TY - JOUR AU - Battipaglia, G. AU - Ruggeri, A. AU - Massoud, R. PY - 2017 DA - 2017// TI - Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia JO - Cancer VL - 123 UR - https://doi.org/10.1002/cncr.30680 DO - 10.1002/cncr.30680 ID - Battipaglia2017 ER - TY - JOUR AU - Battipaglia, G. AU - Massoud, R. AU - Ahmed, S. O. PY - 2019 DA - 2019// TI - Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 mutated acute myeloid leukemia: an update JO - Clin Lymphoma Myeloma Leuk VL - 19 UR - https://doi.org/10.1016/j.clml.2019.04.004 DO - 10.1016/j.clml.2019.04.004 ID - Battipaglia2019 ER - TY - JOUR AU - Bazarbachi, A. AU - Labopin, M. AU - Battipaglia, G. PY - 2019 DA - 2019// TI - Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. a retrospective acute leukemia working party-European Society for Blood and Marrow Transplant Study JO - Clin Hematol Int VL - 1 UR - https://doi.org/10.2991/chi.d.190310.001 DO - 10.2991/chi.d.190310.001 ID - Bazarbachi2019 ER - TY - JOUR AU - Serve, H. AU - Krug, U. AU - Wagner, R. PY - 2013 DA - 2013// TI - Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.4990 DO - 10.1200/JCO.2012.46.4990 ID - Serve2013 ER - TY - JOUR AU - Xuan, L. AU - Wang, Y. AU - Huang, F. PY - 2020 DA - 2020// TI - Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial JO - Lancet Oncol VL - 21 UR - https://doi.org/10.1016/S1470-2045(20)30455-1 DO - 10.1016/S1470-2045(20)30455-1 ID - Xuan2020 ER - TY - JOUR AU - Burchert, A. AU - Bug, G. AU - Fritz, L. V. PY - 2020 DA - 2020// TI - Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN) JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.19.03345 DO - 10.1200/JCO.19.03345 ID - Burchert2020 ER - TY - JOUR AU - Mathew, N. R. AU - Baumgartner, F. AU - Braun, L. PY - 2018 DA - 2018// TI - Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4484 DO - 10.1038/nm.4484 ID - Mathew2018 ER - TY - JOUR AU - Metzelder, S. K. AU - Schroeder, T. AU - Finck, A. PY - 2012 DA - 2012// TI - High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2012.105 DO - 10.1038/leu.2012.105 ID - Metzelder2012 ER - TY - JOUR AU - Romero, D. PY - 2020 DA - 2020// TI - Sorafenib prevents AML relapse after allo-HSCT JO - Nat Rev Clin Oncol VL - 17 UR - https://doi.org/10.1038/s41571-020-00431-7 DO - 10.1038/s41571-020-00431-7 ID - Romero2020 ER - TY - JOUR AU - Sandmaier, B. M. AU - Khaled, S. K. AU - Oran, B. AU - Gammon, G. AU - Trone, D. AU - Frankfurt, O. PY - 2014 DA - 2014// TI - Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell transplantation JO - Blood VL - 124 UR - https://doi.org/10.1182/blood.V124.21.428.428 DO - 10.1182/blood.V124.21.428.428 ID - Sandmaier2014 ER - TY - JOUR AU - Ganguly, S. AU - Cortes, J. E. AU - Krämer, A. PY - 2019 DA - 2019// TI - Clinical outcomes and characteristics of patients (pts) with FLT3-internal tandem duplication (FLT3-ITD)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML) undergoing hematopoietic stem cell transplant (HSCT) after quizartinib (Q) or salvage chemotherapy (SC) in the Quantum-R trial JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-124504 DO - 10.1182/blood-2019-124504 ID - Ganguly2019 ER - TY - JOUR AU - Maziarz, R. T. AU - Patnaik, M. M. AU - Scott, B. L. PY - 2018 DA - 2018// TI - Radius: a phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-113582 DO - 10.1182/blood-2018-99-113582 ID - Maziarz2018 ER - TY - JOUR AU - Levis, M. J. AU - Hamadani, M. AU - Logan, B. R. PY - 2019 DA - 2019// TI - BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+AML JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-124322 DO - 10.1182/blood-2019-124322 ID - Levis2019 ER - TY - JOUR AU - Ward, P. S. AU - Patel, J. AU - Wise, D. R. PY - 2010 DA - 2010// TI - The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate JO - Cancer Cell VL - 17 UR - https://doi.org/10.1016/j.ccr.2010.01.020 DO - 10.1016/j.ccr.2010.01.020 ID - Ward2010 ER - TY - JOUR AU - DiNardo, C. D. AU - Stein, E. M. AU - Botton, S. PY - 2018 DA - 2018// TI - Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1716984 DO - 10.1056/NEJMoa1716984 ID - DiNardo2018 ER - TY - JOUR AU - Yen, K. AU - Travins, J. AU - Wang, F. PY - 2017 DA - 2017// TI - AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1034 DO - 10.1158/2159-8290.CD-16-1034 ID - Yen2017 ER - TY - JOUR AU - Stein, E. M. AU - DiNardo, C. D. AU - Mims, A. S. PY - 2017 DA - 2017// TI - Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial JO - Blood VL - 130 ID - Stein2017 ER - TY - JOUR AU - Konopleva, M. AU - Pollyea, D. A. AU - Potluri, J. PY - 2016 DA - 2016// TI - Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia JO - Cancer Discov VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-16-0313 DO - 10.1158/2159-8290.CD-16-0313 ID - Konopleva2016 ER - TY - JOUR AU - Chua, C. C. AU - Roberts, A. W. AU - Reynolds, J. PY - 2020 DA - 2020// TI - Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.20.00572 DO - 10.1200/JCO.20.00572 ID - Chua2020 ER - TY - JOUR AU - DiNardo, C. D. AU - Jonas, B. A. AU - Pullarkat, V. PY - 2020 DA - 2020// TI - Azacitidine and venetoclax in previously untreated acute myeloid leukemia JO - N Engl J Med VL - 383 UR - https://doi.org/10.1056/NEJMoa2012971 DO - 10.1056/NEJMoa2012971 ID - DiNardo2020 ER - TY - JOUR AU - Kent, A. AU - Pollyea, D. A. AU - Winters, A. AU - Jordan, C. T. AU - Smith, C. AU - Gutman, J. A. PY - 2020 DA - 2020// TI - Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse JO - Blood VL - 136 UR - https://doi.org/10.1182/blood-2020-138832 DO - 10.1182/blood-2020-138832 ID - Kent2020 ER - TY - JOUR AU - DeAngelo, D. J. AU - Spencer, A. AU - Bhalla, K. N. PY - 2013 DA - 2013// TI - Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2013.38 DO - 10.1038/leu.2013.38 ID - DeAngelo2013 ER - TY - JOUR AU - Bug, G. AU - Burchert, A. AU - Wagner, E. M. PY - 2017 DA - 2017// TI - Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2017.242 DO - 10.1038/leu.2017.242 ID - Bug2017 ER - TY - JOUR AU - Wellbrock, J. AU - Latuske, E. AU - Köhler, J. PY - 2015 DA - 2015// TI - Expression of hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1059 DO - 10.1158/1078-0432.CCR-14-1059 ID - Wellbrock2015 ER - TY - JOUR AU - Cortes, J. E. AU - Heidel, F. H. AU - Hellmann, A. PY - 2019 DA - 2019// TI - Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome JO - Leukemia VL - 33 UR - https://doi.org/10.1038/s41375-018-0312-9 DO - 10.1038/s41375-018-0312-9 ID - Cortes2019 ER - TY - JOUR AU - Cortes, J. E. AU - Heidel, F. H. AU - Fiedler, W. PY - 2020 DA - 2020// TI - Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00929-8 DO - 10.1186/s13045-020-00929-8 ID - Cortes2020 ER - TY - JOUR AU - Gebru, M. T. AU - Wang, H. G. PY - 2020 DA - 2020// TI - Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00992-1 DO - 10.1186/s13045-020-00992-1 ID - Gebru2020 ER - TY - JOUR AU - Yan, C. H. AU - Liu, D. H. AU - Liu, K. Y. PY - 2012 DA - 2012// TI - Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-09-380386 DO - 10.1182/blood-2011-09-380386 ID - Yan2012 ER - TY - JOUR AU - Liu, Y. AU - Bewersdorf, J. P. AU - Stahl, M. AU - Zeidan, A. M. PY - 2019 DA - 2019// TI - Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? JO - Blood Rev VL - 34 UR - https://doi.org/10.1016/j.blre.2018.12.001 DO - 10.1016/j.blre.2018.12.001 ID - Liu2019 ER - TY - JOUR AU - Maeda, T. AU - Hosen, N. AU - Fukushima, K. PY - 2013 DA - 2013// TI - Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine JO - Blood Cancer J VL - 3 UR - https://doi.org/10.1038/bcj.2013.29 DO - 10.1038/bcj.2013.29 ID - Maeda2013 ER -